Please enable JS

Investors

Press Releases

 
Press Releases
  Date Title View
May 10, 2005
CAMBRIDGE, Mass., May 10 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, today announced its financial results for the first quarter ended March 31, 2005. For the first quarter 2005, the Company reported a net...
Apr 28, 2005
CAMBRIDGE, Mass., April 28 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Alan Crane, Chairman and Chief Executive Officer, will present at the Morgan Stanley's Third Annual Global Healthcare Unplug...
Apr 27, 2005
CAMBRIDGE, Mass., April 27 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Richard Shea, Vice President and Chief Financial Officer, will present at the Second Annual Rodman & Renshaw Techvest Global...
Apr 25, 2005
CAMBRIDGE, Mass., April 25 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, will report its financial results for the first quarter ended March 31, 2005 before the U.S. financial markets open on Tuesday, May 10, 2005....
Apr 25, 2005
CAMBRIDGE, Mass., April 25 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, today announced that it will hold its Annual Meeting of Stockholders on May 26, 2005 at 8:30 am EDT at the offices of Wilmer Cutler Pickering Hal...
Apr 25, 2005
CAMBRIDGE, Mass., April 25, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Alan Crane, Chairman and Chief Executive Officer, will present at the Deutsche Bank Securities 30th Annual Heal...
Apr 12, 2005
CAMBRIDGE, Mass., April 12 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced senior management promotions. Ganesh Venkataraman, Ph.D., has been promoted to Senior Vice President, Research, and Steven B. Brugger ...
Mar 29, 2005
CAMBRIDGE, Mass., March 29 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Alan Crane, Chairman and Chief Executive Officer, will present at the CIBC World Markets Annual Biotechnology & Specialt...
Mar 17, 2005
CAMBRIDGE, Mass., March 17, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Marsha Fanucci has been elected to Momenta's Board of Directors, replacing John Zabriskie, Ph.D. "I a...
Mar 10, 2005
CAMBRIDGE, Mass., March 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Alan Crane, Chairman and Chief Executive Officer, will present at the SG Cowen 25th Annual Health Care Conferen...
FirstPrevious
...
39
NextLast
= add release to Briefcase